Traumatic Brain Injury and Risk for Chronic Traumatic Encephalopathy (TBI and CTE)
The project is designed to assess early diagnosis of Chronic Traumatic Encephalopathy (CTE), a neurobehavioral syndrome manifested by failed relationships, marriages, and businesses, emotional disturbances, depression, alcohol and substance abuse, and suicide attempts and completions. CTE typically begins after a latency period of several years following single or repeated Traumatic Brain Injuries (TBIs). A history of cerebral concussion may or may not be present.
This study builds upon prior work at UCLA using Positron Emission Tomography (PET) to identify normal and abnormal functional patterns in the brain by studying persons with a history of TBI including but not limited to: amateur and professional athletes, active and veteran members of the armed forces, as well as victims of motor vehicle and work accidents, and physical battery/domestic violence.
This project aims to expand these findings to the population at large. Identification of the syndrome is critical for identifying potential individuals who are most likely to benefit from potential prevention and treatment.
Traumatic Brain Injury
Chronic Traumatic Encephalopathy
Mild Cognitive Impairment
|Study Design:||Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Diagnostic
|Official Title:||FDDNP-PET Imaging in Persons at Risk for Chronic Traumatic Encephalopathy|
- FDDNP PET will detect tau deposits in the brain of living subjects at risk for CTE [ Time Frame: Baseline ]FDDNP signals will be higher in those affected by CTE compared with controls in all subcortical regions and the amygdala areas that produce tau deposits following trauma.
- Correlation of genetic risk factors and FDDNP-PET measurements [ Time Frame: Baseline ]FDDNP-PET measures will vary according to genotypes found to influence age at dementia onset (e.g., apolipoprotein E [APOE]).
- Cognitive Impairment will be observed in subjects at risk of CTE [ Time Frame: Baseline ]Affected subjects will show greater depressive symptoms than controls as well as cognitive impairment.
|Study Start Date:||March 2013|
|Estimated Study Completion Date:||January 2017|
|Estimated Primary Completion Date:||January 2017 (Final data collection date for primary outcome measure)|
[F-18]FDDNP is a molecular imaging probe for PET, with high in vitro binding affinity to NFTs and of the fibrillar tau deposits as shown with fluorescent microscopy with non-radioactive FDDNP.
Show Detailed Description
Please refer to this study by its ClinicalTrials.gov identifier: NCT02003183
|United States, California|
|UCLA Longevity Center|
|Los Angeles, California, United States, 90095|
|Principal Investigator:||Gary W Small, M.D.||UCLA Longevity Center|